Home › Companies › TNGX

Tango Therapeutics

TNGX Lead: Phase 1 ★ Read the deep dive → 6 Biotech Distilled articles ↓

Oncology Small Molecule

Most recent annual filing: 2026-03-05

Pipeline (6 active programs)

vopimetostat

TNG462

Small Molecule Target: PRMT5

Pancreatic Cancer Phase 1 oral Revolution Medicines
Non-Small Cell Lung Cancer Phase 1 oral Revolution Medicines
Undisclosed indication Phase 1 Erasca

TNG456

Small Molecule Target: PRMT5

Glioblastoma Phase 1

TNG961

Small Molecule Target: HBS1L

Undisclosed indication Preclinical

TNG260

Small Molecule Target: CoREST

Non-Small Cell Lung Cancer Phase 1

Discontinued (2)

TNG260 — undisclosed · deprioritized; limited clinical benefit observed; plan to shut down the clinical trial
TNG908 — Glioblastoma · stopped enrollment due to insufficient brain exposure for clinical activity in GBM patients and portfolio prioritization

Biotech Distilled coverage (6)

2026-06-08 UPDATE: Tango Therapeutics (TNGX) - The Combo Hit. 92% ORR.
2026-05-16 UPDATE: Tango Therapeutics (TNGX) – Four Specialists, One Pile-On, and a 19% Two-Day Gap Down 🔒 Paid
2026-05-14 UPDATE: Tango Therapeutics (TNGX) – The Pipeline Just Got a Lot Smaller (and the Smart Money Got Bigger) 🔒 Paid
2026-05-12 UPDATE: Tango Therapeutics (TNGX) – Farallon Steps Into the Seat Third Rock Vacated 🔒 Paid
2026-04-18 UPDATE: Tango Therapeutics (TNGX) – The C-Suite Revolving Door Continues 🔒 Paid
2026-03-18 Tango Therapeutics (TNGX) - Scientific Deep Dive for Vopimetostat and Pipeline Products

Articles open on Substack. Some deep dives are subscriber-only.